Rapamycin enhances the antiproliferative effect of transforming growth factor-β on MCF-7 human breast cancer cells

GUOPING WANG and TAO YIN

Department of Oncology, Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan 610041, P.R. China

Received December 30, 2015; Accepted February 1, 2017

DOI: 10.3892/etm.2017.4557

Abstract. Transforming growth factor-β (TGF-β), a well-known cytokine with pleiotropic biological functions, has an important role in the regulation of cellular proliferation. Rapamycin has specific antigenic activity on the function of the mammalian target of the rapamycin signaling pathway. The cooperation of TGF-β and rapamycin on the proliferation of Michigan Cancer Foundation (MCF)-7 human breast cancer cells is unclear. The present study demonstrated that TGF-β had a growth-arresting effect on MCF-7 cancer cells. TGF-β stimulation resulted in the upregulation of several cyclin-dependent kinase inhibitors, including p14ARF, p15INK4b, p16INK4a and p21WAF1/CIP1. The present study also demonstrated that rapamycin enhances the antiproliferative effect of TGF-β. The combination of rapamycin and TGF-β induced apoptosis of MCF-7 tumor cells. These findings advance the current understanding of the biological effects of TGF-β and rapamycin.

Introduction

Transforming growth factor-β (TGF-β) is a well-known cytokine with pleiotropic biological functions. TGF-β has a pivotal role in various physiological processes and pathological conditions, including development, cancer, senescence, fibrosis, wound healing and tissue regeneration (1-3). As an immunosuppressive cytokine, TGF-β has a key role in tumor immune evasion (4). The levels of TGF-β are often observed to be elevated in the serum of patients with cancer (5). Notably, TGF-β also influences the biological characteristics of cancer stem cells. Research has demonstrated that toll-like receptor 4/NANOG-dependent cancer stem cells are defective in the TGF-β pathway (6). Perivascular TGF-β suppresses proliferation and promotes invasion and heterogeneity in squamous cell carcinoma stem cells (7). Importantly, release from TGF-β-mediated inhibition restores anti-tumor immunity (8).

TGF-β regulates numerous functions of epithelial cells. TGF-β is a well-documented inducer of epithelial-to-mesenchymal transition (EMT) during embryogenesis, cancer progression and fibrosis (9). Both exogenous TGF-β protein and TGF-β from other sources, such as platelets, are able to induce EMT (10,11). Several lines of evidence indicate that TGF-β is able to promote cell proliferation of thyroid epithelial cells (12) and various tumor cells (13,14); however, it also has antiproliferative effects on other cells (15,16). Such conflicting findings suggest that the effects of TGF-β are dependent on cell type and context.

The mammalian target of rapamycin (mTOR) signaling pathway has a critical role in regulating basic cellular functions, including cell proliferation, survival, mobility and angiogenesis (17). Rapamycin has specific antigenic action on the function of mTOR. Rapamycin induces cell cycle arrest in many cells (18,19); however, the combinational effect of rapamycin and TGF-β on tumor cells is unclear. In the present study, it was demonstrated that TGF-β had a cytostatic effect on Michigan Cancer Foundation (MCF)-7 human breast cancer cells. TGF-β induced upregulation of the cyclin-dependent kinase inhibitors (CKIs) p14ARF, p15INK4b, p16INK4a and p21WAF1/CIP1. Notably, it was demonstrated that rapamycin enhanced the antiproliferative effect of TGF-β.

Materials and methods

Cell culture and reagents. Human breast cancer cell line MCF-7 was purchased from American Type Culture Collection (Manassas, VA, USA). Tumor cells were cultured and propagated in Dulbecco’s modified Eagle medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum at 37°C (5% CO₂). Rapamycin was obtained from Selleck Chemicals (Houston, TX, USA) and dissolved in dimethyl sulfoxide. Recombinant human TGF-β1 was purchased from HumanZyme, Inc. (Chicago, IL, USA) and dissolved in 4 mM hydrochloric acid.

Cell viability assay. A total of 5x10⁴ MCF-7 cells were plated on 6-well plastic plates. Cells were treated with 5 and 10 ng/ml

Correspondence to: Dr Tao Yin, Department of Oncology, Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, 17 People’s South Road, Chengdu, Sichuan 610041, P.R. China
E-mail: yintao03073@163.com

Key words: transforming growth factor-β, rapamycin, breast cancer, proliferation

EXPERIMENTAL AND THERAPEUTIC MEDICINE 14: 748-752, 2017
TGF-β, in the presence or absence of 100 nM rapamycin, or an equivalent volume of vehicles. Cell number was counted manually 120 h after treatment. An MTT assay was performed using 96-well plates in order to determine cell viability. A total of 2.5x10^4 cells per well were seeded in the 96-well plates. Tumor cells were exposed to 10 ng/ml TGF-β and/or 100 nM rapamycin on the following day. Tumor cell viability was evaluated at 0, 24, 48, 72, 96 and 120 h after experiment initiation. For the MTT assay, 20 µl MTT reagent (5 mg/ml) was added to all wells and the plates were incubated for an additional 4 h at 37˚C. Subsequently, the formazan precipitates in the cells were dissolved in 150 µl dimethyl sulfoxide after removal of the supernatant. Absorbance was determined at 570 nm and a growth curve was plotted.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from tumor tissues using an RNA isolation kit (Axxygen, Tewksbury, MA, USA). RNA was then treated with DNase to remove genomic DNA and subsequently reverse transcribed (PrimeScript RT reagent kit with gDNA Eraser; Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's instructions. qPCR was performed on a CFX 96 real-time PCR thermocycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using specific primers and SYBR Green supermix (Takara Biotechnology Co., Ltd.). RT-qPCR experimental procedures were performed according to the manufacturer's protocol with some changes (SYBR Premix Ex Taq II; Takara Biotechnology Co., Ltd.). The total PCR reaction volume was 25 µl, which contained 12.5 µl supermix, 9.5 µl H₂O, 1 µl cDNA, 1 µl forward primers and 1 µl reverse primers. PCR conditions were as follows: Initial denaturation for 30 sec at 95˚C, 40 cycles at 95˚C for 5 sec, 60˚C for 30 sec, 15 sec at 95˚C and 5 sec at 65˚C. Primers used for qPCR have previously been published (20). The sequences were as follows: p4ARF, forward 5'-TCTCTCAGTGAAGGAGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGAACCATGGTGCCAGGGTTCTGT-3'; p15INK4b, forward 5'-GGGGTGCCCTTCTTCA-3'; p16INK4a, forward 5'-GAGTGCCCTTCTCTTCA-3'; and GAPDH, forward 5'-GAAGGAGCTTACACGACTTGCAGTGAATGAGGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGGAGGGTTCTTCTTGGA-3'; and GAPDH, forward 5'-GAAGGAGCTTACACGACTTGCAGTGAATGAGGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGGAGGGTTCTTCTTGGA-3'; and GAPDH, forward 5'-GAAGGAGCTTACACGACTTGCAGTGAATGAGGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGGAGGGTTCTTCTTGGA-3'; and GAPDH, forward 5'-GAAGGAGCTTACACGACTTGCAGTGAATGAGGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGGAGGGTTCTTCTTGGA-3'; and GAPDH, forward 5'-GAAGGAGCTTACACGACTTGCAGTGAATGAGGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGGAGGGTTCTTCTTGGA-3'; and GAPDH, forward 5'-GAAGGAGCTTACACGACTTGCAGTGAATGAGGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGGAGGGTTCTTCTTGGA-3'; and GAPDH, forward 5'-GAAGGAGCTTACACGACTTGCAGTGAATGAGGGTGAATGAGCGTACGAGG-3' and reverse 5'-AGGAGGGTTCTTCTTGGA-3'. Relative gene expression levels were quantified using the 2-ΔΔCq method with GAPDH as reference (21). PCR was repeated in triplicate.

Flow cytometric analysis. A total of 5x10^4 MCF-7 cells were plated on 6-well plastic plates and treated with 10 ng/ml TGF-β and/or 100 nM rapamycin, or an equivalent volume of vehicles. After 72 h, cells were harvested and stained with annexin-V-FITC and propidium iodide (PI). Apoptotic cells were quantified using a FACSCalibur flow cytometer and analyzed using CellQuest software (version 6.0; BD Biosciences, San Jose, CA, USA).

Statistical analysis. Statistical significance was determined using Student's t-tests between two groups, and one-way analysis of variance was used when comparing more than three groups followed by least significant difference and Student-Newman-Keuls analysis. SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Results were expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

TGF-β exhibits a cytostatic effect on MCF-7 tumor cells. To investigate whether TGF-β influences the proliferation of tumor cells, human breast cancer MCF-7 cells were incubated with 5 or 10 ng/ml concentrations of human TGF-β. Results demonstrated that TGF-β decreased cell numbers in a dose-dependent manner. A dose of 10 ng/ml TGF-β significantly impaired tumor cell proliferation compared with vehicle controls (P<0.05; Fig. 1A). A 5 ng/ml dose of TGF-β also exhibited a significant cytostatic effect on MCF-7 cell proliferation (P<0.05), although to a lesser extent when compared with the 10 ng/ml dose (Fig. 1A). The MTT assay was adapted to assess the viability of tumor cells in the presence of 10 ng/ml TGF-β. In the presence of TGF-β, the viability of MCF-7 cells was significantly reduced compared with the vehicle group from 48 h onwards (P<0.05; Fig. 1B). It was therefore concluded that TGF-β exhibited a cytostatic effect on MCF-7 tumor cells.

TGF-β modulates cell cycle regulators. Considering that TGF-β had a cytostatic effect on MCF-7 tumor cells, the effect of TGF-β on the induction of CKIs was investigated. Following exposure to TGF-β, the expression of cell-cycle inhibitors p14ARF, p15INK4b, p16INK4a and p21WAF1/CIP1 was assessed. RT-qPCR analysis demonstrated that TGF-β significantly increased the expression levels of p15INK4b, p16INK4a and p21WAF1/CIP1 in MCF-7 cells compared with vehicle controls (P<0.05; Fig. 2); it also increased p14ARF, though this was not statistically significant. This suggests that TGF-β may have a potential regulatory role in CKI expression.

Rapamycin enhances the antiproliferative effect of TGF-β. The influence of rapamycin, a well-known mTOR inhibitor, on the antiproliferative effect of TGF-β was investigated. MCF-7 cells were exposed to 100 nM rapamycin and 5 or 10 ng/ml TGF-β. MTT assay demonstrated that rapamycin significantly inhibited MCF-7 cell viability compared with vehicle controls after 48 h of experiment initiation. Unexpectedly, it was demonstrated that in the presence of both rapamycin and TGF-β, MCF-7 cells proliferated significantly slower compared with the single treatments of rapamycin or TGF-β (P<0.05; Fig. 3). These results suggest that rapamycin enhances the antiproliferative effect of TGF-β.

Combination treatment with rapamycin and TGF-β induces apoptosis. An investigation was conducted in order to determine whether the combination of rapamycin and TGF-β was able to induce apoptosis of MCF-7 tumor cells. MCF-7 cells were treated with 100 nM rapamycin and 10 ng/ml TGF-β for 5 days, and subsequently the cells were stained with annexin-V-FITC and PI. Enumeration of the percentage of viable cells by flow cytometry demonstrated that neither rapamycin nor TGF-β alone induced apoptosis; however, a significant decrease in cell viability was observed in the
The present study demonstrated that TGF-β exhibited cytostatic effects on human breast adenocarcinoma MCF-7 cells, which may be associated with the upregulation of CKIs, including p14ARF, p15INK4b, p16INK4a, and p21WAF1/CIP1. It was also demonstrated that rapamycin enhanced the antiproliferative effect of TGF-β. In addition, rapamycin and TGF-β induced apoptosis of MCF-7 tumor cells.

TGF-β is involved in a variety of processes, including proliferation, differentiation, apoptosis, adhesion, EMT, and extracellular matrix deposition, which are essential for tissue homeostasis (1). In the present study, it was demonstrated that recombinant TGF-β inhibited the proliferation of MCF-7 cells. This result was consistent with a previous study by Mazars et al (22). Porcine TGF-β1 was used in the study by Mazars et al (22), whereas the present study used recombinant human TGF-β, which was more suitable for the physiological conditions. CKIs have been demonstrated to be causally associated with the inhibitory effect of TGF-β; in ovarian cancer cells, TGF-β decreases cyclin-dependent kinase 2 activity and induces p21WAF1/CIP1 (23). Other studies have demonstrated that the effect of TGF-β on growth inhibition is mediated by Smad complexes with forkhead box O factors, which activate p15INK4b and p21WAF1/CIP1 (24,25). TGF-β has also been demonstrated to suppress transcription of the Myc gene; in breast cancer cells that are insensitive to TGF-β, the defective repression of Myc is frequently observed (26). TGF-β inhibits cell proliferation by inhibiting c-Myc expression accompanied by the induction of p15 and p21 expression (27,28). The transcription factor CCAAT-enhancer binding protein β, essential for the induction of p15INK4b and the repression of c-Myc, has been demonstrated to be central to the cytostatic program initiated by TGF-β (25).
The results of the present study demonstrated that, in MCF-7 tumor cells, TGF-β induced the expression of p14^ARF, p15^INK4b, p16^INK4a, and p21^WAF1/CIP1, which may be associated with the growth-arresting effects of TGF-β. Notably, it has been reported that the response of fibroblasts and epithelial cells to TGF-β differs, with TGF-β increasing the proliferation of fibroblasts and inducing cell cycle arrest of epithelial cells (29). TGF-β also functions to maintain the pool of quiescent hematopoietic stem cells (30). Notably, TGF-β transcriptionally activates p21, which stabilizes nuclear factor (erythroid-derived 2)-like 2, enhancing glutathione metabolism and diminishing the effectiveness of anticancer therapeutics (7).

mTOR complex 1 is a critical regulator of Gap 1 (G1) cell cycle progression and rapamycin is able to induce G1 cell cycle arrest in MDA-MB-231 breast cancer cells (19). The present study demonstrated that 100 nM rapamycin alone was able to inhibit the proliferation of MCF-7 cells. This effect may be associated with the relatively low levels of phospholipase D activity in MCF-7 cells (31). The present study demonstrated, for the first time, that rapamycin enhances the growth-arresting effect of TGF-β on MCF-7 tumor cells. Therefore, it is now evident that low doses of rapamycin are sufficient for activating TGF-β signaling (18). Rapamycin-induced G1 cell cycle arrest employs both TGF-β and retinoblastoma pathways (19), which may partly explain the combinational action of TGF-β and rapamycin. Neither 100 nM rapamycin nor 10 ng/ml TGF-β alone induced apoptosis in MCF-7 cells; however, the combination of both rapamycin and TGF-β resulted in significant apoptosis. The induction of apoptosis by TGF-β has been demonstrated to be cell type-dependent. TGF-β induces apoptosis in thymocytes, and p27^kip1 reduction is a key event in this process (16). Further investigation is required to clarify the mechanism of the combinational effect of TGF-β and rapamycin on apoptosis.

In conclusion, the present study demonstrated that rapamycin enhances the antiproliferative effect of TGF-β on human MCF-7 tumor cells. These findings advance the current understanding of the biological effects of TGF-β and rapamycin.

Acknowledgements

This research was supported by the National Natural Science Foundation of China (grant no. 81501609) and the China Post-doctoral Science Foundation (grant no. 2015MS582553).

References